Fig. 1 · Structure

Documents & Downloads

Trazodone HCl

Cat. No. A11703 CAS 25332-39-2
Trazodone is an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) class. It is a phenylpiperazine compound. Trazodone also has anti-anxiety (anxiolytic) and sleep-inducing (hypnotic) effects.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Trazodone HCl Research Summary

This section summarizes 4 in vivo studies of Trazodone HCl from 3 published references. In vivo models include RML-infected tg37+/− mice; APP/PS1 mice.

Trazodone HCl In Vivo Studies

In RML-infected mice receiving Trazodone HCl, some treated animals developed neurologically definite clinical prion disease. In APP/PS1 mice, oral Trazodone treatment resulted in differential gene expression in the cerebral cortices. In prion model mice, Trazodone HCl significantly rescued hippocampal synapse density compared with prion-only animals, although not to wild-type levels. In tau model mice, Trazodone HCl reduced p-tau levels, whereas DBM did not. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Clinical prion disease in infected mice

Animal study · RML-infected tg37+/− mice [1]

RML-infected tg37+/− mice received Trazodone HCl intraperitoneally once daily, with vehicle-treated animals as controls. Some trazodone-treated mice developed neurologically definite clinical prion disease.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
neurologically definite clinical prion diseaseclinical prion disease 40 mg/kg: 3/15 trazodone-treated mice[1]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
once daily; from 7 weeks post-infection until terminal clinical sign appeared
Vehicle
sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Trazodone HCl 40 mg/kgvehicle-treated animals (n = 20)Only 3/15 trazodone-treated and 6/21 DBM-treated mice developed neurologically definite clinical prion disease (83 ± 4 days and 84 ± 4 days, respectively).[1]
Trazodone HCl 40 mg/kg
Model: RML-infected tg37+/− mice
Methods and source locations

Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Prion infection of mice (S54); Materials and methods > Pharmacological treatment of mice (S57, S58); Results > Trazodone and dibenzoylmethane prevent neurological signs of prion disease in prion-infected mice (S154, S157); Table 1 legend (S254, S255)

neurologically definite clinical prion disease: neurologically definite clinical prion disease; comparator: vehicle-treated animals (n = 20) — Materials and methods > Pharmacological treatment of mice (S57); Table 1 legend (S255)

Trazodone HCl 40 mg/kg · Materials and methods > Pharmacological treatment of mice (S57, S58); Table 1 legend (S255)

Cortical gene expression in amyloid model mice

Animal study · APP/PS1 mice [2]

APP/PS1 mice received Trazodone by oral gavage. Compared with untreated controls, treatment resulted in differential gene expression in the cerebral cortices, with 842 genes upregulated and 503 downregulated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
differentially expressed genes (DEGs) in the cerebral corticesdifferential gene expression 10 mg/kg body weight per day: 842 genes upregulated and 503 downregulated[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
14 consecutive days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Trazodone 10 mg/kg body weight per dayuntreated control (CTRL)Trazodone treatment resulted in the differential expression of 1,345 genes (false discovery rate (FDR)-adjusted P < 0.05], including 842 upregulated and 503 downregulated genes[2]
Trazodone 10 mg/kg body weight per day
Model: APP/PS1 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Trazodone

The paper names Trazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11703. No dose conversion or lot validation.

Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Materials and Methods > In Vivo Administration of Trazodone in Mice and Tissue Collection. (S62); Fig. 3. legend (S107)

differentially expressed genes (DEGs) in the cerebral cortices: differentially expressed genes (DEGs) in the cerebral cortices; comparator: untreated control (CTRL) — Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Fig. 3. legend (S107)

Trazodone 10 mg/kg body weight per day · Results > Trazodone Treatment Downregulates sST2 and Ameliorates Amyloid Pathology in APP/PS1 Transgenic Mice. (S8); Results > Trazodone Treatment Restores the Expression of Synaptic Genes in APP/PS1 Transgenic mice. (S28); Materials and Methods > In Vivo Administration of Trazodone in Mice and Tissue Collection. (S62)

Hippocampal Synapse Density Following Treatment

Animal study · Prion tg37+/− mice [3]

Prion tg37+/− mice received Trazodone HCl intraperitoneally. Compared with prion-only animals, treatment significantly rescued hippocampal synapse density, although not to wild-type levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Synapse number quantification of the hippocampal CA1 neuropilsynapse density 4.54 synapses/55 μm2[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
once daily; from 8 to 10 weeks post-inoculation (wpi)
Vehicle
saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Trazodone HCl 40 mg/kgprion only and control (NBH) animals2 weeks of trazodone treatment significantly rescued synapse density (to 4.54 synapses/55 μm2; P = 0.0096), although not to wild-type levels[3]
Trazodone HCl 40 mg/kg
Model: Prion tg37+/− mice
Methods and source locations

Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Prion infection, pharmacological treatment and metabolic labelling (S1, S2); Materials and methods > Electron microscopy (S70); Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157); Figure 5 legend (S207)

Synapse number quantification of the hippocampal CA1 neuropil: Synapse number quantification of the hippocampal CA1 neuropil; comparator: prion only and control (NBH) animals — Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157); Figure 5 legend (S207)

Trazodone HCl 40 mg/kg · Materials and methods > Prion infection, pharmacological treatment and metabolic labelling (S2); Results > Quantitative and functional rescue of synapses and mitochondria by trazodone (S157)

Phosphorylated tau levels in tau model mice

Animal study · rTg4510 tauP301L+ mice [1]

rTg4510 tauP301L+ mice received Trazodone HCl intraperitoneally once daily. Trazodone, but not DBM, reduced p-tau levels measured by the AT100 antibody.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p-tau levels measured by the AT100 antibodyReported result 40 mg/kg; once daily; from 4 months until 8 months: Trazodone but not DBM reduces levels.[1]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
once daily; from 4 months until 8 months
Vehicle
sterile saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Trazodone HCl 40 mg/kgvehicle- or DBM-treated mice40 mg/kg; once daily; from 4 months until 8 months: Trazodone but not DBM reduces levels.[1]
Trazodone HCl 40 mg/kg
Model: rTg4510 tauP301L+ mice
Methods and source locations

Compound reported in the paper: Trazodone HCl; Compound label in the paper: Trazodone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Pharmacological treatment of mice (S57, S58); Results > Trazodone and dibenzoylmethane are neuroprotective in the rTg4510 model of frontotemporal dementia (S199); Figure 4 legend (S239, S244, S245)

p-tau levels measured by the AT100 antibody: p-tau levels measured by the AT100 antibody; comparator: vehicle- or DBM-treated mice — Materials and methods > Pharmacological treatment of mice (S57, S58); Figure 4 legend (S244, S245)

Trazodone HCl 40 mg/kg · Materials and methods > Pharmacological treatment of mice (S57, S58); Figure 4 legend (S245)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 25332-39-2
Formula C19H22ClN5O.HCl
Molecular Weight 408.32
Synonyms Desyrel
SMILES
C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (9.79 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Trazodone HCl Research References

  1. [1] Halliday M, Radford H, Zents KAM, et al. Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice. Brain (2017). PMID: 28430857 DOI: 10.1093/brain/awx074 Source material
  2. [2] Wong DYK, Fu WY, Uhm H, et al. Repurposing trazodone for Alzheimer's disease to modulate soluble ST2 levels and alleviate Alzheimer's pathology. Proc Natl Acad Sci U S A (2026). PMID: 42446992 DOI: 10.1073/pnas.2536489123 Source material
  3. [3] Albert-Gasco H, Smith HL, Alvarez-Castelao B, et al. Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration. Brain (2024). PMID: 37703312 DOI: 10.1093/brain/awad313 Source material

Added to your cart

View Cart Checkout
Loading...